High Human Papillomavirus Vaccine Acceptability and Cost-Effectiveness of the Chinese 2-Valent Vaccine Among Men Who Have Sex With Men: A Cross-Sectional Study in Shenyang, China
Background: Despite the insupportable burden caused by the human papillomavirus (HPV) and high vaccine acceptability, vaccination programs are not currently available for men who have sex with men (MSM). We aimed to assess HPV infection by examining the willingness for vaccination among MSM and cost...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-11-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2021.763564/full |
| _version_ | 1798033020277489664 |
|---|---|
| author | Ze-Hao Ye Ze-Hao Ye Ze-Hao Ye Ze-Hao Ye Zhao-Zhen Liu Zhao-Zhen Liu Zhao-Zhen Liu Zhao-Zhen Liu Si-Tong Cui Si-Tong Cui Si-Tong Cui Si-Tong Cui Zhen-Xing Chu Zhen-Xing Chu Zhen-Xing Chu Zhen-Xing Chu Yong-Jun Jiang Yong-Jun Jiang Yong-Jun Jiang Yong-Jun Jiang Jun-Jie Xu Jun-Jie Xu Jun-Jie Xu Jun-Jie Xu Qing-Hai Hu Qing-Hai Hu Qing-Hai Hu Qing-Hai Hu Hong Shang Hong Shang Hong Shang Hong Shang |
| author_facet | Ze-Hao Ye Ze-Hao Ye Ze-Hao Ye Ze-Hao Ye Zhao-Zhen Liu Zhao-Zhen Liu Zhao-Zhen Liu Zhao-Zhen Liu Si-Tong Cui Si-Tong Cui Si-Tong Cui Si-Tong Cui Zhen-Xing Chu Zhen-Xing Chu Zhen-Xing Chu Zhen-Xing Chu Yong-Jun Jiang Yong-Jun Jiang Yong-Jun Jiang Yong-Jun Jiang Jun-Jie Xu Jun-Jie Xu Jun-Jie Xu Jun-Jie Xu Qing-Hai Hu Qing-Hai Hu Qing-Hai Hu Qing-Hai Hu Hong Shang Hong Shang Hong Shang Hong Shang |
| author_sort | Ze-Hao Ye |
| collection | DOAJ |
| description | Background: Despite the insupportable burden caused by the human papillomavirus (HPV) and high vaccine acceptability, vaccination programs are not currently available for men who have sex with men (MSM). We aimed to assess HPV infection by examining the willingness for vaccination among MSM and cost-effectiveness of the Chinese 2-valent HPV vaccine.Methods: We recruited MSM in Shenyang, China between July and December 2020 to conduct anal HPV testing and an online survey regarding HPV-related knowledge and vaccine acceptability. We performed a cost-effectiveness analysis to evaluate the incremental cost-effectiveness ratios (ICERs) of the Chinese 2-valent HPV vaccine.Results: A total of 234 participants completed the online survey; of those, 203 were successfully tested for HPV. The median age was 30 years [interquartile range (IQR): 23–38 years]. Most participants had at least undergraduate education (136/234, 58.1%). The acceptability rate for the free HPV vaccine was 57.7% (135/234). The prevalence of HPV types 16 and 18 was 14.9% (18/121) and 26.8% (22/82) in the willing and unwilling to vaccinate groups, respectively (P > 0.05). The prevalence of high-risk HPV among participants aged <30 and ≥50 years was 48.6 and 38.9%, respectively. Using the Chinese per capita gross domestic product (GDP) as a threshold, the Chinese 2-valent HPV vaccine would be a “very cost-effective” strategy, with an ICER value of USD 4,411. This evidence showed that the Chinese 2-valent HPV vaccine was more cost-effective than other imported vaccines.Conclusions: Targeted strategies should be utilized in MSM with different rates of vaccine acceptability. A pilot HPV vaccination program based on the Chinese 2-valent HPV vaccine for MSM is urgently warranted to reduce the burden of HPV and anal cancer. |
| first_indexed | 2024-04-11T20:22:27Z |
| format | Article |
| id | doaj.art-1dbc4c92254e461685cbf6c98593f6f9 |
| institution | Directory Open Access Journal |
| issn | 2296-858X |
| language | English |
| last_indexed | 2024-04-11T20:22:27Z |
| publishDate | 2021-11-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj.art-1dbc4c92254e461685cbf6c98593f6f92022-12-22T04:04:46ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2021-11-01810.3389/fmed.2021.763564763564High Human Papillomavirus Vaccine Acceptability and Cost-Effectiveness of the Chinese 2-Valent Vaccine Among Men Who Have Sex With Men: A Cross-Sectional Study in Shenyang, ChinaZe-Hao Ye0Ze-Hao Ye1Ze-Hao Ye2Ze-Hao Ye3Zhao-Zhen Liu4Zhao-Zhen Liu5Zhao-Zhen Liu6Zhao-Zhen Liu7Si-Tong Cui8Si-Tong Cui9Si-Tong Cui10Si-Tong Cui11Zhen-Xing Chu12Zhen-Xing Chu13Zhen-Xing Chu14Zhen-Xing Chu15Yong-Jun Jiang16Yong-Jun Jiang17Yong-Jun Jiang18Yong-Jun Jiang19Jun-Jie Xu20Jun-Jie Xu21Jun-Jie Xu22Jun-Jie Xu23Qing-Hai Hu24Qing-Hai Hu25Qing-Hai Hu26Qing-Hai Hu27Hong Shang28Hong Shang29Hong Shang30Hong Shang31National Health Commission Key Laboratory of AIDS Immunology (China Medical University), National Clinical Research Center for Laboratory Medicine, The First Affiliated Hospital of China Medical University, Shenyang, ChinaKey Laboratory of AIDS Immunology, Chinese Academy of Medical Sciences, Shenyang, ChinaKey Laboratory of AIDS Immunology of Liaoning Province, Shenyang, ChinaCollaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou, ChinaNational Health Commission Key Laboratory of AIDS Immunology (China Medical University), National Clinical Research Center for Laboratory Medicine, The First Affiliated Hospital of China Medical University, Shenyang, ChinaKey Laboratory of AIDS Immunology, Chinese Academy of Medical Sciences, Shenyang, ChinaKey Laboratory of AIDS Immunology of Liaoning Province, Shenyang, ChinaCollaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou, ChinaNational Health Commission Key Laboratory of AIDS Immunology (China Medical University), National Clinical Research Center for Laboratory Medicine, The First Affiliated Hospital of China Medical University, Shenyang, ChinaKey Laboratory of AIDS Immunology, Chinese Academy of Medical Sciences, Shenyang, ChinaKey Laboratory of AIDS Immunology of Liaoning Province, Shenyang, ChinaCollaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou, ChinaNational Health Commission Key Laboratory of AIDS Immunology (China Medical University), National Clinical Research Center for Laboratory Medicine, The First Affiliated Hospital of China Medical University, Shenyang, ChinaKey Laboratory of AIDS Immunology, Chinese Academy of Medical Sciences, Shenyang, ChinaKey Laboratory of AIDS Immunology of Liaoning Province, Shenyang, ChinaCollaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou, ChinaNational Health Commission Key Laboratory of AIDS Immunology (China Medical University), National Clinical Research Center for Laboratory Medicine, The First Affiliated Hospital of China Medical University, Shenyang, ChinaKey Laboratory of AIDS Immunology, Chinese Academy of Medical Sciences, Shenyang, ChinaKey Laboratory of AIDS Immunology of Liaoning Province, Shenyang, ChinaCollaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou, ChinaNational Health Commission Key Laboratory of AIDS Immunology (China Medical University), National Clinical Research Center for Laboratory Medicine, The First Affiliated Hospital of China Medical University, Shenyang, ChinaKey Laboratory of AIDS Immunology, Chinese Academy of Medical Sciences, Shenyang, ChinaKey Laboratory of AIDS Immunology of Liaoning Province, Shenyang, ChinaCollaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou, ChinaNational Health Commission Key Laboratory of AIDS Immunology (China Medical University), National Clinical Research Center for Laboratory Medicine, The First Affiliated Hospital of China Medical University, Shenyang, ChinaKey Laboratory of AIDS Immunology, Chinese Academy of Medical Sciences, Shenyang, ChinaKey Laboratory of AIDS Immunology of Liaoning Province, Shenyang, ChinaCollaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou, ChinaNational Health Commission Key Laboratory of AIDS Immunology (China Medical University), National Clinical Research Center for Laboratory Medicine, The First Affiliated Hospital of China Medical University, Shenyang, ChinaKey Laboratory of AIDS Immunology, Chinese Academy of Medical Sciences, Shenyang, ChinaKey Laboratory of AIDS Immunology of Liaoning Province, Shenyang, ChinaCollaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou, ChinaBackground: Despite the insupportable burden caused by the human papillomavirus (HPV) and high vaccine acceptability, vaccination programs are not currently available for men who have sex with men (MSM). We aimed to assess HPV infection by examining the willingness for vaccination among MSM and cost-effectiveness of the Chinese 2-valent HPV vaccine.Methods: We recruited MSM in Shenyang, China between July and December 2020 to conduct anal HPV testing and an online survey regarding HPV-related knowledge and vaccine acceptability. We performed a cost-effectiveness analysis to evaluate the incremental cost-effectiveness ratios (ICERs) of the Chinese 2-valent HPV vaccine.Results: A total of 234 participants completed the online survey; of those, 203 were successfully tested for HPV. The median age was 30 years [interquartile range (IQR): 23–38 years]. Most participants had at least undergraduate education (136/234, 58.1%). The acceptability rate for the free HPV vaccine was 57.7% (135/234). The prevalence of HPV types 16 and 18 was 14.9% (18/121) and 26.8% (22/82) in the willing and unwilling to vaccinate groups, respectively (P > 0.05). The prevalence of high-risk HPV among participants aged <30 and ≥50 years was 48.6 and 38.9%, respectively. Using the Chinese per capita gross domestic product (GDP) as a threshold, the Chinese 2-valent HPV vaccine would be a “very cost-effective” strategy, with an ICER value of USD 4,411. This evidence showed that the Chinese 2-valent HPV vaccine was more cost-effective than other imported vaccines.Conclusions: Targeted strategies should be utilized in MSM with different rates of vaccine acceptability. A pilot HPV vaccination program based on the Chinese 2-valent HPV vaccine for MSM is urgently warranted to reduce the burden of HPV and anal cancer.https://www.frontiersin.org/articles/10.3389/fmed.2021.763564/fullhuman papillomavirusvaccinemen who have sex with menacceptabilitycost-effectivenessChina |
| spellingShingle | Ze-Hao Ye Ze-Hao Ye Ze-Hao Ye Ze-Hao Ye Zhao-Zhen Liu Zhao-Zhen Liu Zhao-Zhen Liu Zhao-Zhen Liu Si-Tong Cui Si-Tong Cui Si-Tong Cui Si-Tong Cui Zhen-Xing Chu Zhen-Xing Chu Zhen-Xing Chu Zhen-Xing Chu Yong-Jun Jiang Yong-Jun Jiang Yong-Jun Jiang Yong-Jun Jiang Jun-Jie Xu Jun-Jie Xu Jun-Jie Xu Jun-Jie Xu Qing-Hai Hu Qing-Hai Hu Qing-Hai Hu Qing-Hai Hu Hong Shang Hong Shang Hong Shang Hong Shang High Human Papillomavirus Vaccine Acceptability and Cost-Effectiveness of the Chinese 2-Valent Vaccine Among Men Who Have Sex With Men: A Cross-Sectional Study in Shenyang, China Frontiers in Medicine human papillomavirus vaccine men who have sex with men acceptability cost-effectiveness China |
| title | High Human Papillomavirus Vaccine Acceptability and Cost-Effectiveness of the Chinese 2-Valent Vaccine Among Men Who Have Sex With Men: A Cross-Sectional Study in Shenyang, China |
| title_full | High Human Papillomavirus Vaccine Acceptability and Cost-Effectiveness of the Chinese 2-Valent Vaccine Among Men Who Have Sex With Men: A Cross-Sectional Study in Shenyang, China |
| title_fullStr | High Human Papillomavirus Vaccine Acceptability and Cost-Effectiveness of the Chinese 2-Valent Vaccine Among Men Who Have Sex With Men: A Cross-Sectional Study in Shenyang, China |
| title_full_unstemmed | High Human Papillomavirus Vaccine Acceptability and Cost-Effectiveness of the Chinese 2-Valent Vaccine Among Men Who Have Sex With Men: A Cross-Sectional Study in Shenyang, China |
| title_short | High Human Papillomavirus Vaccine Acceptability and Cost-Effectiveness of the Chinese 2-Valent Vaccine Among Men Who Have Sex With Men: A Cross-Sectional Study in Shenyang, China |
| title_sort | high human papillomavirus vaccine acceptability and cost effectiveness of the chinese 2 valent vaccine among men who have sex with men a cross sectional study in shenyang china |
| topic | human papillomavirus vaccine men who have sex with men acceptability cost-effectiveness China |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2021.763564/full |
| work_keys_str_mv | AT zehaoye highhumanpapillomavirusvaccineacceptabilityandcosteffectivenessofthechinese2valentvaccineamongmenwhohavesexwithmenacrosssectionalstudyinshenyangchina AT zehaoye highhumanpapillomavirusvaccineacceptabilityandcosteffectivenessofthechinese2valentvaccineamongmenwhohavesexwithmenacrosssectionalstudyinshenyangchina AT zehaoye highhumanpapillomavirusvaccineacceptabilityandcosteffectivenessofthechinese2valentvaccineamongmenwhohavesexwithmenacrosssectionalstudyinshenyangchina AT zehaoye highhumanpapillomavirusvaccineacceptabilityandcosteffectivenessofthechinese2valentvaccineamongmenwhohavesexwithmenacrosssectionalstudyinshenyangchina AT zhaozhenliu highhumanpapillomavirusvaccineacceptabilityandcosteffectivenessofthechinese2valentvaccineamongmenwhohavesexwithmenacrosssectionalstudyinshenyangchina AT zhaozhenliu highhumanpapillomavirusvaccineacceptabilityandcosteffectivenessofthechinese2valentvaccineamongmenwhohavesexwithmenacrosssectionalstudyinshenyangchina AT zhaozhenliu highhumanpapillomavirusvaccineacceptabilityandcosteffectivenessofthechinese2valentvaccineamongmenwhohavesexwithmenacrosssectionalstudyinshenyangchina AT zhaozhenliu highhumanpapillomavirusvaccineacceptabilityandcosteffectivenessofthechinese2valentvaccineamongmenwhohavesexwithmenacrosssectionalstudyinshenyangchina AT sitongcui highhumanpapillomavirusvaccineacceptabilityandcosteffectivenessofthechinese2valentvaccineamongmenwhohavesexwithmenacrosssectionalstudyinshenyangchina AT sitongcui highhumanpapillomavirusvaccineacceptabilityandcosteffectivenessofthechinese2valentvaccineamongmenwhohavesexwithmenacrosssectionalstudyinshenyangchina AT sitongcui highhumanpapillomavirusvaccineacceptabilityandcosteffectivenessofthechinese2valentvaccineamongmenwhohavesexwithmenacrosssectionalstudyinshenyangchina AT sitongcui highhumanpapillomavirusvaccineacceptabilityandcosteffectivenessofthechinese2valentvaccineamongmenwhohavesexwithmenacrosssectionalstudyinshenyangchina AT zhenxingchu highhumanpapillomavirusvaccineacceptabilityandcosteffectivenessofthechinese2valentvaccineamongmenwhohavesexwithmenacrosssectionalstudyinshenyangchina AT zhenxingchu highhumanpapillomavirusvaccineacceptabilityandcosteffectivenessofthechinese2valentvaccineamongmenwhohavesexwithmenacrosssectionalstudyinshenyangchina AT zhenxingchu highhumanpapillomavirusvaccineacceptabilityandcosteffectivenessofthechinese2valentvaccineamongmenwhohavesexwithmenacrosssectionalstudyinshenyangchina AT zhenxingchu highhumanpapillomavirusvaccineacceptabilityandcosteffectivenessofthechinese2valentvaccineamongmenwhohavesexwithmenacrosssectionalstudyinshenyangchina AT yongjunjiang highhumanpapillomavirusvaccineacceptabilityandcosteffectivenessofthechinese2valentvaccineamongmenwhohavesexwithmenacrosssectionalstudyinshenyangchina AT yongjunjiang highhumanpapillomavirusvaccineacceptabilityandcosteffectivenessofthechinese2valentvaccineamongmenwhohavesexwithmenacrosssectionalstudyinshenyangchina AT yongjunjiang highhumanpapillomavirusvaccineacceptabilityandcosteffectivenessofthechinese2valentvaccineamongmenwhohavesexwithmenacrosssectionalstudyinshenyangchina AT yongjunjiang highhumanpapillomavirusvaccineacceptabilityandcosteffectivenessofthechinese2valentvaccineamongmenwhohavesexwithmenacrosssectionalstudyinshenyangchina AT junjiexu highhumanpapillomavirusvaccineacceptabilityandcosteffectivenessofthechinese2valentvaccineamongmenwhohavesexwithmenacrosssectionalstudyinshenyangchina AT junjiexu highhumanpapillomavirusvaccineacceptabilityandcosteffectivenessofthechinese2valentvaccineamongmenwhohavesexwithmenacrosssectionalstudyinshenyangchina AT junjiexu highhumanpapillomavirusvaccineacceptabilityandcosteffectivenessofthechinese2valentvaccineamongmenwhohavesexwithmenacrosssectionalstudyinshenyangchina AT junjiexu highhumanpapillomavirusvaccineacceptabilityandcosteffectivenessofthechinese2valentvaccineamongmenwhohavesexwithmenacrosssectionalstudyinshenyangchina AT qinghaihu highhumanpapillomavirusvaccineacceptabilityandcosteffectivenessofthechinese2valentvaccineamongmenwhohavesexwithmenacrosssectionalstudyinshenyangchina AT qinghaihu highhumanpapillomavirusvaccineacceptabilityandcosteffectivenessofthechinese2valentvaccineamongmenwhohavesexwithmenacrosssectionalstudyinshenyangchina AT qinghaihu highhumanpapillomavirusvaccineacceptabilityandcosteffectivenessofthechinese2valentvaccineamongmenwhohavesexwithmenacrosssectionalstudyinshenyangchina AT qinghaihu highhumanpapillomavirusvaccineacceptabilityandcosteffectivenessofthechinese2valentvaccineamongmenwhohavesexwithmenacrosssectionalstudyinshenyangchina AT hongshang highhumanpapillomavirusvaccineacceptabilityandcosteffectivenessofthechinese2valentvaccineamongmenwhohavesexwithmenacrosssectionalstudyinshenyangchina AT hongshang highhumanpapillomavirusvaccineacceptabilityandcosteffectivenessofthechinese2valentvaccineamongmenwhohavesexwithmenacrosssectionalstudyinshenyangchina AT hongshang highhumanpapillomavirusvaccineacceptabilityandcosteffectivenessofthechinese2valentvaccineamongmenwhohavesexwithmenacrosssectionalstudyinshenyangchina AT hongshang highhumanpapillomavirusvaccineacceptabilityandcosteffectivenessofthechinese2valentvaccineamongmenwhohavesexwithmenacrosssectionalstudyinshenyangchina |